Radiopharm Theranostics (ASX: RAD) has completed enrolment in its Phase 2b RAD 101 brain metastases imaging trial with interim data showing 90% concordance with MRI, while progressing early-stage trials of therapeutic candidates RAD 202, RV-01, and RAD 402. The company reported a $19.2 million cash balance at quarter end, down from $34.5 million, with a net operating cash outflow of $14.9 million driven by milestone-related R&D and staff costs.
- 90% concordance in RAD 101 Phase 2b imaging trial
- RAD 202 Phase 0/1 data show tumor uptake and safety
- Two new First-In-Human trials initiated for RV-01 and RAD 402
- Quarter-end cash balance $19.2 million, down from $34.5 million
- Company expects cash burn to moderate and plans equity financing
Phase 2b RAD 101 Trial Hits Key Milestone
Radiopharm Theranostics has wrapped up enrolment in its U.S. Phase 2b clinical trial of RAD 101, an imaging agent targeting fatty acid synthase for patients with recurrent brain metastases. Interim results from 20 patients reveal a 90% concordance rate with MRI; the trial's primary endpoint; reinforcing earlier Phase 2a findings. This level of diagnostic alignment, if sustained in the full cohort, paves the way for a planned multi-centre Phase 3 registrational trial, a crucial step toward regulatory approval. The company has secured a supply agreement with Siemens Healthineers to radiolabel and distribute RAD 101 with Fluorine-18, enhancing its commercial readiness.
RAD 202 Shows Promise in Early HER2+ Trial
In parallel, Radiopharm presented initial data for its therapeutic candidate RAD 202 at the American Association for Cancer Research conference, confirming meaningful tumor uptake and a favourable safety profile in the lowest dose cohort. The Phase 0/1 HEAT trial targets HER2-positive advanced solid tumors, a validated oncology target. Following a positive recommendation from the Data and Safety Monitoring Committee, the trial is advancing to a higher dose level of 130mCi. The company expects to complete enrolment in this cohort and report further data by mid-2026. These developments align with earlier positive safety and biodistribution data, supporting continued clinical progression of RAD 202, as detailed in Radiopharm's recent coverage of its promising safety and tumor uptake profile in the early HER2+ trial.
Pipeline Expansion with New First-In-Human Trials
Radiopharm has initiated two additional First-In-Human clinical trials this quarter. The RV-01 trial, developed through Radiopharm Ventures in collaboration with MD Anderson Cancer Center, targets the B7H3 immune checkpoint protein across various tumor types. The first patient was dosed in February 2026 in a Phase 1/2a study designed to establish safety and dosing parameters. Separately, RAD 402, a monoclonal antibody targeting KLK3 for advanced prostate cancer, entered a Phase 1 dose escalation trial with its first patient dosed in March 2026. These new trials underscore Radiopharm's platform productivity and disciplined pipeline expansion strategy.
Financial Position and Cash Flow Dynamics
Radiopharm reported a closing cash balance of $19.2 million at 31 March 2026, down from $34.5 million at the prior quarter's end. The $14.9 million net cash outflow from operating activities was predominantly driven by research and development expenses and staff costs, which together accounted for 95% of operating spend. The company highlighted that this elevated burn rate reflects deliberate, milestone-driven investment, including advancement of the RAD 202 Phase 1 HEAT trial to dose level 3, first patient dosing in RAD 402 and RV-01 studies, and completion of RAD 101 Phase 2b enrolment with interim data release.
Administration and corporate costs included non-recurring professional services related to dual-listing compliance and the implementation of an At-The-Market Facility completed in December 2025, expected to normalize in the coming quarter. Radiopharm's board does not expect the current quarter's cash burn to represent the ongoing run rate, anticipating moderation in Q4 FY2026 and beyond.
Funding Strategy and Outlook
The company is actively assessing alternative capital sources to support its clinical programs. It maintains access to an At-The-Market Facility established in December 2025, with the capacity to raise up to US$18.9 million via American Depositary Receipts issuance. Additionally, Radiopharm expects to receive approximately $5 million from the FY25 Australian R&D Tax Incentive in the coming months. Cash management measures, such as delaying discretionary operating activities, are also in place to extend runway. The board remains confident in the company's ability to continue operations and meet business objectives based on these funding avenues and strategic cost controls.
Bottom Line?
Radiopharm's clinical progress is encouraging but sustaining development hinges on successful capital management amid a cash runway of just over one quarter.
Questions in the middle?
- Will Radiopharm confirm RAD 101’s diagnostic performance in the full Phase 2b cohort to trigger Phase 3?
- How will escalating RAD 202’s dose impact safety and efficacy outcomes in HER2-positive tumors?
- Can Radiopharm secure sufficient equity or non-dilutive funding to maintain momentum beyond Q4 2026?